Synapse - Brigitte Senechal

Results (47)

Role of cell therapy product characteristics in patient response to TAK-940 (CD19(T2)28z1xx chimeric antigen receptor (CAR) T): Biomarker analyses from a phase i study in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Sundaresan, V.; Senechal, B.; Wang, X.; Kashyap, S.; Tong, E.; Joshi, A.; Dash, A.; Sellner, L.; Chen, S.; McAvoy, D.; more...
Blood (2023)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of a high-sensitivity assay for detection of chimeric antigen receptor T-cell vectors using low-partition digital PCR technology

Journal Article

Arcila, M. E.; Patel, U.; Momeni-Boroujeni, A.; Yao, J.; Chan, R.; Chan, J.; Rijo, I.; Yu, W.; Chaves, N.; Patel, H.; more...
Journal of Molecular Diagnostics (2023)

Fulltext@MSK | Save

Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy

Meeting Abstract

Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
Clinical Pharmacology & Therapeutics (2023)

Fulltext@MSK | Save

A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma

Meeting Abstract

Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials

Meeting Abstract

Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
Blood (2022)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
Blood (2022)

Fulltext@MSK | Save

GPRC5D-targeted CAR T cells for myeloma

Journal Article

Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
New England Journal of Medicine (2022)

Fulltext@MSK | Save

Autologous car T cell product from COVID-19-positive patient: Manufacturing and regulatory considerations

Meeting Abstract

Sikder, D.; Senechal, B.; Wang, X.; Geyer, M.; Riviere, I.
Cytotherapy (2022)

Fulltext@MSK | Save